R&D channel feed

Ap­plied Ther­a­peu­tics says rare dis­ease drug fails PhI­II tri­al, still plans to seek ap­proval

3 years ago

4D Mol­e­c­u­lar Ther­a­peu­tics ac­quires eye dis­ease as­set from Fortress Biotech sub­sidiary

3 years ago
Deals

Lil­ly will test its weight loss drug di­rect­ly against No­vo Nordisk's We­govy

3 years ago
Pharma

On Ver­tex and CRISPR Ther­a­peu­tics’ heels, blue­bird sub­mits sick­le cell gene ther­a­py to FDA

3 years ago
Cell/Gene Tx
FDA+

Uni­ty touts PhII win, plots head-to-head with Re­gen­eron drug in 'defin­ing mo­men­t'

3 years ago

As­traZeneca, Io­n­is un­veil full PhI­II da­ta for 'mega brand' AT­TR drug

3 years ago
Pharma

Apel­lis’ ex­pan­sion plans in­to ALS face road­block

3 years ago

An­a­lysts ex­pect qui­et first quar­ter as Big Phar­ma earn­ings be­gin to roll in

3 years ago

Phar­maEssen­tia se­cures $462M+ to fur­ther growth of Besre­mi and its pipeline

3 years ago
Financing

Jun­shi Bio­sciences touts lung can­cer da­ta as it looks to ex­pand PD-1 la­bel in Chi­na again

3 years ago

BeiGene notch­es win for PD-1 drug in stom­ach can­cers. When will part­ner No­var­tis sub­mit for ap­proval?

3 years ago

Up­dat­ed: In­di­an CD­MO opens 'ded­i­cat­ed' R&D site for Schrödinger as part of five-year agree­ment

3 years ago

AACR roundup: Merus eyes ac­cel­er­at­ed ap­proval; Im­muneer­ing ac­cel­er­ates RAS drug

3 years ago

FDA's pain ad­comm de­bates clin­i­cal tri­al de­signs for opi­oid post-mar­ket­ing tri­als

3 years ago
Pharma
FDA+

Karyopharm stock drops af­ter in­hibitor's PhI da­ta show low­er dose not as ef­fec­tive: #AACR23

3 years ago

In a leaked ab­stract, J&J's cell ther­a­py ap­pears to have dra­mat­ic ben­e­fits for mul­ti­ple myelo­ma pa­tients

3 years ago
Pharma
Cell/Gene Tx

KRAS, one of can­cer’s tough­est tar­gets, sees a surge of new ther­a­pies try­ing to lim­it side ef­fects: #AACR23

3 years ago

Palleon un­veils PhI look at 'lawn mow­er' ap­proach to gly­coim­munol­o­gy: #AACR23

3 years ago
People

Basilea push­es back FDA sub­mis­sion for an­tibi­ot­ic over CMO is­sues

3 years ago
Manufacturing

So­cial me­dia is fu­el­ing en­thu­si­asm for new weight loss drugs. Are reg­u­la­tors watch­ing?

3 years ago
Marketing

#trek­for­to­mor­row: Ear­ly lessons from the trail

3 years ago
People
Biotech Voices

PhRMA calls doc­u­ment de­struc­tion part of new guid­ance on drug price ne­go­ti­a­tions 'un­con­sti­tu­tion­al'

3 years ago
Law

Kin­nate Bio­phar­ma touts ear­ly ef­fi­ca­cy in pan-RAF pro­gram: #AACR23

3 years ago

Vax­cyte un­veils new da­ta on chal­lenger to Pfiz­er’s Pre­vnar, heads to­ward PhI­II

3 years ago
First page Previous page 90919293949596 Next page Last page
A service from the Financial Times